Immunovo, founded in 2009, is a Dutch biotechnology company focused on advancing cancer treatment through pioneering immune activation technology. The company's primary emphasis lies in its proprietary Immune Activation System (IAS), which combines synthetic peptide antigens with a novel immune stimulant (adjuvant). Immunovo's dedication to the discovery and clinical development of immunotherapeutics for oncology places it within the Biotechnology and Pharmaceutical industries.
The latest investment in Immunovo was a Seed Round investment on 28 April 2010, which saw participation from Biox Biosciences and Lupus Ventures. With a strong focus on leveraging innovative technology to enhance cancer treatment, Immunovo's commitment to revolutionizing immunotherapeutics positions it as an intriguing prospect for venture capital investment.
